Contact this trialFirst, we need to learn more about you.
PARP Inhibitor, CDK Inhibitor
Veliparib + Dinaciclib for Advanced Cancers
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing the side effects and best dose of two drugs, veliparib and dinaciclib, for treating patients with solid tumors that have spread. The drugs may stop the growth of tumor cells by blocking enzymes needed for cell growth.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service